HC Wainwright Reaffirms “Buy” Rating for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $55.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 56.65% from the company’s current price. HC Wainwright also issued estimates for TG Therapeutics’ FY2025 earnings at $1.39 EPS, FY2026 earnings at $2.27 EPS and FY2027 earnings at $2.86 EPS.

Other analysts have also recently issued reports about the company. JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. The Goldman Sachs Group raised their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Stock Down 1.4 %

Shares of TG Therapeutics stock opened at $35.11 on Tuesday. The stock has a 50-day simple moving average of $30.86 and a 200-day simple moving average of $28.33. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $36.94. The firm has a market cap of $5.47 billion, a price-to-earnings ratio of -351.06 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. On average, equities research analysts expect that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System raised its holdings in TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock valued at $1,283,000 after acquiring an additional 364 shares in the last quarter. Blue Trust Inc. raised its holdings in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 371 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in TG Therapeutics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 463 shares in the last quarter. Private Advisor Group LLC raised its holdings in TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after acquiring an additional 542 shares in the last quarter. Finally, Brookstone Capital Management raised its holdings in shares of TG Therapeutics by 3.7% during the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 624 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.